Gwyn Lo (ethinyl estradiol, norelgestromin)

Where it stands

Gwyn Lo (ethinyl estradiol, norelgestromin) was approved by the US FDA on 2026-07-28 under NDA219990. The sponsor is Viatris Specialty. The records classify the approval as a "new formulation or manufacturer" and list the milestone as an official FDA approval.

The records do not give a therapeutic area or an indication. They also give no strength, dosage form, route of administration, labelled population or launch timing. The same active substance combination is authorised in the EU as Evra, which is the only related product in the records. The records do not say whether Gwyn Lo is a version of, or linked to, Evra, so the Evra entry should be read as context only.

Regulatory pathway and designations

The only designation in the records is "New formulation or manufacturer". Gwyn Lo was approved as an NDA (NDA219990), meaning the FDA's new drug application framework. The records do not say whether it is a full NDA, a 505(b)(2) application or another route. They also do not say whether it relied on data from a reference product, so the evidence package cannot be assessed from this information.

No expedited designations (priority review, fast track, breakthrough) are recorded. No PDUFA date, review-cycle history or advisory committee activity is given. The CHMP opinion date is blank, as expected for a US-only record. The EU status of the same substance (Evra, authorised) comes from a separate EU authorisation and does not carry over to this US approval.

Safety and pharmacovigilance

The records contain no safety information for Gwyn Lo. They give no label text, boxed warning, contraindications, risk management requirements or postmarketing commitments, so none are described here.

As a general point, products containing an estrogen and a progestin are usually regulated with class-level safety considerations, and the FDA label is the authoritative source for these. Readers should check the approved prescribing information once it is available. Routine US postmarketing pharmacovigilance applies to any approved NDA product, including adverse event reporting to the FDA. The records do not show whether any product-specific requirements were added.

What to watch

The main gap is the approved labelling. Once the FDA documents are public, check the indication, dosage form and strength, the safety sections, and whether the approval relied on a reference product. These will show what "new formulation or manufacturer" means in practice.

Also watch for Viatris Specialty's launch plans, any relationship to the EU-authorised Evra, and any postmarketing requirements. None of these are in the current records, so any view on them would be speculation.